Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00277433 · ClinicalTrials.gov registry record
Histamine Pharmacogenetics in Children With Atopic Dermatitis
A clinical trial of Dermatitis, Atopic, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- 751
- Enrollment target
- 7
- Study locations
NCT00277433: Completed study of Dermatitis, Atopic, sponsored by Virginia Commonwealth University.
NCT00277433 is a study of Dermatitis, Atopic that has completed, run by Virginia Commonwealth University. The registered enrollment target is 751 participants, above the 371-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (102% higher). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00277433, a study of Dermatitis, Atopic, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- 751 participants
- Enrollment target
- 7
- Study locations
Study Summary
The primary goal of the study is to investigate the impact of a common genetic polymorphism in a histamine detoxification enzyme that may well have a common role in regulating the expression of atopic dermatitis (AD) and other related atopic diseases in children.
Conditions Studied
Interventions
- OTHER Buccal Swab
Study Locations (7)
Arkansas
- Arkansas Children's Hospital - Little Rock
California
- University of California at San Diego - San Diego
District of Columbia
- Children's National Medical Center - Washington D.C.
Kentucky
- Kosair Charities Pediatric Clinical Research Unit - Louisville
Michigan
- Wayne State University/Children's Hospital of Michigan - Detroit
Missouri
- Children's Mercy Hospital - Kansas City
Texas
- Baylor College of Medicine/Texas Children's Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 751 participants |
| Start Date | 2004-06 |
| Est. Completion | 2009-12 |
What the finished NCT00277433 record still lists
NCT00277433 is an observational study that tracks outcomes without assigning an intervention. The registered 751 participants enrollment target is mid-sized for trials with a published cap, above the 371-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (102% higher).
The record links to 1 condition, with Dermatitis, Atopic appearing as the primary indexed condition, and to 1 intervention - of which Buccal Swab is the first listed.
NCT00277433 lists 7 locations in 7 states (Arkansas, California, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT00277433 about?
NCT00277433 is a clinical study titled "Histamine Pharmacogenetics in Children With Atopic Dermatitis". The primary goal of the study is to investigate the impact of a common genetic polymorphism in a histamine detoxification enzyme that may well have a common role in regulating the expression of atopic dermatitis (AD) and other related atopic diseases in children.
What is the current status of trial NCT00277433?
This trial is currently completed. The enrollment target is 751 participants. The study started on 2004-06. Estimated completion is 2009-12.
What conditions does trial NCT00277433 study?
This clinical trial studies the following conditions: Dermatitis, Atopic.
What interventions are being tested in trial NCT00277433?
The interventions under investigation include: Buccal Swab (OTHER).
Who is sponsoring clinical trial NCT00277433?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00277433 being conducted?
This trial has 7 study locations across Arkansas, California, District of Columbia, Kentucky, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis, Atopic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00277433's enrollment target sits among peer trials
751 5th of 29 higher than 25 of 29 other Dermatitis, Atopic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dermatitis, Atopic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
RECRUITING · NA
-
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
RECRUITING
-
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06559306 · 752 participants · Phase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia